Cullen Discusses Severe Oral Mucositis Management With Avasopasem
Elizabeth R. Cullen, MSN, ARNP, talks severe oral mucositis management for patients with locally advanced head and neck cancer.
Elizabeth Cullen Discusses Avasopasem Manganese As A Potential Mucositis Management Strategy in Head and Neck Cancers
Elizabeth R. Cullen, MSN, ARNP, provides an overview of avasopasem manganese and its potential role in reducing severe oral mucositis for patients undergoing radiotherapy.
Durvalumab Plus Guadecitabine Shows Early Activity in Checkpoint Inhibitor–Naïve ccRCC
The overall response rate with durvalumab and guadecitabine was 23% in patients with advanced ccRCC who had received 1 or fewer therapies.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512